Form 4: Stoke Therapeutics Executive Sells Shares to Cover Tax Obligations

A Stoke Therapeutics executive sold shares to cover tax liabilities related to vesting restricted stock units.

Summary

• Barry C. Ticho, Chief Medical Officer of Stoke Therapeutics, sold 2,586 shares of common stock on December 9, 2024.
• The sale was mandated by the company to cover tax withholding liabilities associated with the vesting of restricted stock units.
• The shares were sold at a weighted average price of $12.9913 per share.
• The transactions occurred at prices ranging from $12.99 to $13.13 per share.

Sentiment

Score: 5

Explanation: The document describes a routine transaction for tax purposes, which is neither positive nor negative for the company's overall outlook.

Industry Context

Executive stock sales are a common occurrence, particularly to cover tax obligations related to equity compensation. This transaction is not unusual and is a normal part of executive compensation practices.

Comparison to Industry Standards

• Executive stock sales for tax purposes are a standard practice across the industry.
• Many companies use restricted stock units as part of their compensation packages, which often trigger tax liabilities upon vesting.
• The price range of $12.99 to $13.13 per share is within the normal fluctuations of stock prices for companies in the biotechnology sector.

Stakeholder Impact

• The stock sale has a minimal impact on shareholders as it is a routine transaction for tax purposes.

Key Dates

Keywords

Stoke Therapeutics, stock sale, executive, tax liabilities, restricted stock units, STOK